Jardiance Mortality Claim Narrowly Endorsed By FDA Advisory Committee

The 12-11 vote supporting new indication for reduced incidence of cardiovascular death provides cover for FDA if it decides more data are needed before granting first CV benefit claim to a diabetes drug.